Evidence map›Paper›PMID 40505818›Full record

ArticleToxicology and applied pharmacology2025

Unveiling the acute toxic pathology and transcriptomic signature of ocular exposure to phosgene oxime using an in vivo mouse model: A novel pilot study.

Ebenezar Okoyeocha, Natalie Vredevoogd, Shreya Paithankar, Bryan Masino, Poojya Anantharam, Dinesh Goswami, Charlotte Madigan, Megha Suresh, Dodd Sledge, Bin Chen and 1 more

Abstract read
In one paragraph

Article in Toxicology and applied pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ebenezar OkoyeochaDepartment of Pharmacology and Toxicology, College of Osteopathic Medicine, Michigan State University, East Lansing, MI, USA.
Natalie VredevoogdDepartment of Pharmacology and Toxicology, College of Osteopathic Medicine, Michigan State University, East Lansing, MI, USA.
Shreya PaithankarDepartment of Pharmacology and Toxicology, College of Osteopathic Medicine, Michigan State University, East Lansing, MI, USA.
Bryan MasinoDepartment of Pharmacology and Toxicology, College of Osteopathic Medicine, Michigan State University, East Lansing, MI, USA.
Poojya AnantharamMRIGlobal, Kansas City, MO, USA.
Dinesh GoswamiDepartment of Pharmacology and Toxicology, College of Osteopathic Medicine, Michigan State University, East Lansing, MI, USA.
Charlotte MadiganDepartment of Pharmacology and Toxicology, College of Osteopathic Medicine, Michigan State University, East Lansing, MI, USA.
Megha SureshDepartment of Pharmacology and Toxicology, College of Osteopathic Medicine, Michigan State University, East Lansing, MI, USA.
Dodd SledgeMichigan State University Veterinary Diagnostic Laboratory, Lansing, MI, USA.
Bin ChenDepartment of Pharmacology and Toxicology, College of Osteopathic Medicine, Michigan State University, East Lansing, MI, USA; Department of Pediatrics and Human Development, College of Human Medicine, Michigan State University, East Lansing, MI, USA.
Neera Tewari-SinghDepartment of Pharmacology and Toxicology, College of Osteopathic Medicine, Michigan State University, East Lansing, MI, USA. Electronic address: tewarisi@msu.edu.

Funding

Understanding Mustard Vesicants Distribution and Toxicity in the Eye Using In Vivo and In Silico ModelsR01EY034140 · NEI · MICHIGAN STATE UNIVERSITY · PI GERMAN, CARRIE, TEWARI-SINGH, NEERA · 2023 to 2025
$1.5M
Targeted Therapeutic Approaches to Counteract Toxicity from Phosgene Oxime Skin ExposureU01AR075470 · NIAMS · MICHIGAN STATE UNIVERSITY · PI TEWARI-SINGH, NEERA · 2019 to 2021
$1.4M
Treatment strategies for ocular toxicity from chloropicrinR21EY032740 · NEI · MICHIGAN STATE UNIVERSITY · PI TEWARI-SINGH, NEERA · 2021 to 2023
$587k
NEI NIH HHS R01 EY034140NEI NIH HHS R21 EY032740NIAMS NIH HHS U01 AR075470
6 · The paper itself

Abstract

Phosgene oxime (CX), a toxic nettle and highly dangerous urticating vesicant, is a potential chemical threat agent. Exposure to CX is a concern due to its penetrative property, resulting in immediate damage to the skin, lungs, and eye tissues. Although the eye is the most sensitive organ to chemical exposures including CX, there is a lack of research on CX, with a knowledge gap on its toxic effects and the mechanism(s) of ocular injuries. This novel pilot study investigated the toxic pathophysiological effects of CX exposure in mouse ocular tissue. The eyeballs of C57BL/6 mice were either unexposed (sham) or exposed to CX for 15 or 30 s, and eyes were collected for assessments 24 h after exposure, following euthanasia. CX exposure caused a significant degradation of the corneal epithelial layer, increased cellularity of the corneal stroma, loss of endothelial cells, and indicated damage to the ciliary body, lens, and the retina. RNA sequencing using DESeq2 (p-value ≤0.01 and |log2-Fold Change| ≥ 1) identified 697 downregulated and 233 upregulated genes after ocular CX exposure. Functional pathway enrichment using Kyoto Encyclopedia of Genes and Genomes pathway enrichment revealed upregulation of pathways mainly related to inflammation (including cytokines) and cell death including ferroptosis, and downregulation of pathways mainly related to metabolism and tight junction, This pilot study will facilitate in designing further comprehensive studies aimed at, developing relevant CX-induced acute and delayed ocular injury models, and in identifying injury biomarkers and associated mechanisms.

Indexed as

Chemical Warfare AgentsEyeOximesPhosgeneTranscriptomeAnimalsGene Expression ProfilingMaleMiceMice, Inbred C57BLPilot ProjectsChemical Warfare AgentsOximesPhosgeneChemical warfare agentInjury biomarkersOcular chemical exposureOcular injury modelPhosgene oxime

Identifiers

PMID40505818
PMCPMC12378991

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.